UNSPSC 51391809: Mephentermine sulfate

This classification denotes a cns stimulant with the molecular formula 2C11H17N.H2O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 580655Z8RR, chemically known as phenethylamine, n,alpha,alpha-trimethyl-, sulfate (2:1) but more generally known as mephentermine sulfate, which bears US NIH Compound Identifier 71611. European Medicines Agency schedules Mephentermine sulfate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03156MIG.

Most nations, for tariff and trade purposes, schedule mephentermine sulfate under HS 29214980 and SITC 51454. As of Q4 2014, MEPHENTERMINE SULFATE remains US FDA's Preferred Term for this commodity. Mephentermine sulfate bears US NLM identifiers UMLS ID C0282231 and NCI Concept Code C66090. SMILES: CC(C)(CC1CCCCC1)NC.CC(C)(CC1CCCCC1)NC.OS(=O)(=O)O.

UNSPSC 51391809 Mephentermine sulfate, a Commodity code, nominally covers individual pharmaceutical agents, but recent state and local solicitations tagged to this code show minimal direct procurement of mephentermine itself. Instead, the tagged opportunities involve broader pharmaceutical and pharmacy-benefit procurement — naloxone and drug deactivation systems for emergency response and community health, and strategic sourcing models for prescription fulfillment through state health agencies. State and local governments buying under this code frame purchases as components of public health initiatives, emergency medical supply chains, and pharmacy benefit administration rather than as standalone chemical products. Issuing bodies include county health departments and state health and human services commissions conducting both direct product procurement and market-intelligence gathering to reshape pharmacy delivery and cost management.

Recent activity centers in Florida and Texas. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building, response due July 26, 2023, structured as a two-year contract with one-year renewal option. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, designed to establish direct relationships between state pharmacy benefit programs and pharmaceutical manufacturers outside traditional pharmacy benefit manager and group purchasing organization channels. The RFI functioned as preliminary market intelligence rather than a formal competitive solicitation, with no award values or formal evaluation criteria specified at that stage. Neither opportunity shows explicit set-aside designations for disadvantaged enterprises.